2022年7月12日 · Mavyret and Epclusa are both prescription drugs that treat hepatitis C. Learn how their side effects, cost, uses, and interactions compare.

Compare Epclusa vs Mavyret head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

2019年4月22日 · Gilead Sciences’ Epclusa (sofosbuvir/velpatasvir) and AbbVie’s Mavyret (glecaprevir/pibrentasvir) have very high hepatitis C virus (HCV) cure rates in real-world use, aidsmap reports. Both regimens are approved to treat all genotypes of the virus.

2018年10月20日 · Both Mavyret and Epclusa give cure rates above 97% for all genotypes of Hepatitis C except for G3 where both give a cure rate of around 95%. It appears that people with cirrhosis or who have failed previous treatments would get …

treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used. 5 Duration of 12 weeks is recommended for HIV/HCV co-infection.

2018年11月16日 · Both Mavyret and Epclusa give cure rates above 97% for all genotypes of Hepatitis C except for G3 where both give a cure rate of around 95%. It appears that people with cirrhosis or who have failed previous treatments would get …

2022年7月13日 · Mavyret vs. Epclusa You may wonder how Mavyret compares to other medications that are prescribed for similar uses. Here we look at how Mavyret and Epclusa are alike and different.

2024年1月25日 · Epclusa and Mavyret are both FDA-approved to treat hepatitis C virus (HCV). They’re both used to treat all six genotypes in people without cirrhosis or with compensated cirrhosis.

Compare Mavyret head-to-head with other drugs for uses, ratings, cost, side effects and interactions.

2021年4月21日 · Mavyret and Epclusa are both combination prescription drugs used to help cure hepatitis C. Although Mavyret and Epclusa are similar, they have differences, too. Keep reading to learn how these drugs compare. Note: For more information about these drugs, see the in-depth articles on Mavyret and Epclusa.